Page 69 - Drug Class Review
P. 69
Drug Effectiveness Review Project
Alzheimer classification: Mild-moderate
Groups similar at baseline: NR
rivastigmine 4 mg/d placebo rivastigmine 6 mg/d 70.80 68.68 68.62 NR NR NR NR NR NR NR NR NR Primary Outcome Measures: CGIC Secondary Outcome Measures: FOME; Digit Symbol Substitution test; BVR; Trail Making test; NOSGER; MMSE Timing of assessments: Baseline and weeks 7 and 13 Health Outcome Measures: No statistically significant differences between RIV and placebo for NOSGER Intermediate Outcome Measures: Significantly more patients on RIV 6 mg/d than on placebo had marked or moderate improvements on CGIC (42.7% vs. 29.9%; P = 0.05); 4 mg/d diff
• • • • •
Final Report Update 1 Authors: Agid et al. Year: 1998 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: Other germane population qualities: OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
